Cargando…

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

OBJECTIVE: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage. METHODS: This was a post hoc analysis of longi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calabresi, Peter A, Arnold, Douglas L, Sangurdekar, Dipen, Singh, Carol M, Altincatal, Arman, de Moor, Carl, Engle, Bob, Goyal, Jaya, Deykin, Aaron, Szak, Suzanne, Kieseier, Bernd C, Rudick, Richard A, Plavina, Tatiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414824/ https://www.ncbi.nlm.nih.gov/pubmed/33307998 http://dx.doi.org/10.1177/1352458520972573

Ejemplares similares

Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode
por: Plavina, Tatiana, et al.
Publicado: (2020)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Calabresi, Peter A., et al.
Publicado: (2021)

Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform
por: Lee, Stephen, et al.
Publicado: (2022)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014)

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
por: Cutter, Gary, et al.
Publicado: (2023)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

A classification based framework for quantitative description of large-scale microarray data
por: Sangurdekar, Dipen P, et al.
Publicado: (2006)

The association of DNA damage response and nucleotide level modulation with the antibacterial mechanism of the anti-folate drug Trimethoprim
por: Sangurdekar, Dipen P, et al.
Publicado: (2011)

Reconstruction of Escherichia coli transcriptional regulatory networks via regulon-based associations
por: Zare, Hossein, et al.
Publicado: (2009)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density
por: Rao, Mala V., et al.
Publicado: (2002)

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
por: Arnold, Douglas L., et al.
Publicado: (2017)

Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis
por: Edwards, Keith R., et al.
Publicado: (2013)

Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS
por: Hersh, Carrie M, et al.
Publicado: (2021)

Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction
por: Pedersen, Annie, et al.
Publicado: (2019)

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
por: Bar-Or, Amit, et al.
Publicado: (2022)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Transient Growth Arrest in Escherichia coli Induced by Chromosome Condensation
por: Edwards, Andrea L., et al.
Publicado: (2013)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis
por: Bienkowska, Jadwiga, et al.
Publicado: (2014)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Changes in neurofilament transport coincide temporally with alterations in the caliber of axons in regenerating motor fibers
Publicado: (1985)

Absence of the Mid-sized Neurofilament Subunit Decreases Axonal Calibers, Levels of Light Neurofilament (NF-L), and Neurofilament Content
por: Elder, Gregory A., et al.
Publicado: (1998)

Differential dynamics of neurofilament-H protein and neurofilament-L protein in neurons
Publicado: (1994)

Neurofilament deficiency in quail caused by nonsense mutation in neurofilament-L gene
Publicado: (1993)

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
por: Reder, Anthony T., et al.
Publicado: (2021)

A motor for neurofilaments
por: Dove, Alan W.
Publicado: (2002)

Antibody decoration of neurofilaments
Publicado: (1981)

Partial purification of neurofilament subunits from bovine brains and studies on neurofilament assembly
Publicado: (1981)

Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments
por: Ackerley, Steven, et al.
Publicado: (2003)

Neurofilament-dependent Radial Growth of Motor Axons and Axonal Organization of Neurofilaments Does Not Require the Neurofilament Heavy Subunit (NF-H) or Its Phosphorylation
por: Rao, Mala V., et al.
Publicado: (1998)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Neurofilament subunit NF-H modulates axonal diameter by selectively slowing neurofilament transport
Publicado: (1996)

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
por: Gaetani, Lorenzo, et al.
Publicado: (2018)

Neurofilaments are obligate heteropolymers in vivo
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_s262u33dfc19uveppp4dr1ceq2